361 related articles for article (PubMed ID: 29247691)
21. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
22. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
23. Robust Immune Responses Elicited by a Hybrid Adjuvant Based on β-Glucan Particles from Yeast for the Hepatitis B Vaccine.
Liu H; Meng Z; Wang H; Zhang S; Huang Z; Geng X; Guo R; Wu Z; Hong Z
ACS Appl Bio Mater; 2021 Apr; 4(4):3614-3622. PubMed ID: 35014447
[TBL] [Abstract][Full Text] [Related]
24. Nanogram doses of alum-adjuvanted HBs antigen induce humoral immune response in mice when orally administered.
Kapusta J; Pniewski T; Wojciechowicz J; Bociag P; Płucienniczak A
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):143-51. PubMed ID: 20165988
[TBL] [Abstract][Full Text] [Related]
25. Diverse immune responses to HBV surface epitope variants after vaccine booster in adolescents immunized in infancy.
Lai MW; Liang KH; Yeh CT
Clin Microbiol Infect; 2019 Sep; 25(9):1140-1146. PubMed ID: 30771531
[TBL] [Abstract][Full Text] [Related]
26. [Are teenagers immunized in infancy still protected against hepatitis B?].
Pokorska-Lis M; Marczyńska M
Przegl Lek; 2010; 67(1):13-7. PubMed ID: 20509565
[TBL] [Abstract][Full Text] [Related]
27. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand.
Ito H; Kanbe A; Hara A; Ishikawa T
Virology; 2019 May; 531():233-239. PubMed ID: 30928701
[TBL] [Abstract][Full Text] [Related]
28. Potential Hepatitis B Vaccine Formulation Prepared by Uniform-Sized Lipid Hybrid PLA Microparticles with Adsorbed Hepatitis B Surface Antigen.
Liu Q; Chen X; Jia J; Lu T; Yang T; Wang L
Mol Pharm; 2018 Nov; 15(11):5227-5235. PubMed ID: 30350642
[TBL] [Abstract][Full Text] [Related]
29. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
30. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
31. [Reciprocal priming-boosting role of HBsAg and DNA vaccines].
Zhou Z; Chen WS; Zhang HH; Yao JL
Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):212-4. PubMed ID: 12716517
[TBL] [Abstract][Full Text] [Related]
32. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.
Schirmbeck R; Melber K; Mertens T; Reimann J
J Virol; 1994 Mar; 68(3):1418-25. PubMed ID: 8107205
[TBL] [Abstract][Full Text] [Related]
33. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
Oka Y; Akbar SM; Horiike N; Joko K; Onji M
Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.
Akbar SM; Abe M; Masumoto T; Horiike N; Onji M
J Hepatol; 1999 May; 30(5):755-64. PubMed ID: 10365798
[TBL] [Abstract][Full Text] [Related]
35. Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen.
Qiu S; Wei Q; Liang Z; Ma G; Wang L; An W; Ma X; Fang X; He P; Li H; Hu Z
Hum Vaccin Immunother; 2014; 10(8):2350-6. PubMed ID: 25424942
[TBL] [Abstract][Full Text] [Related]
36. Manipulating the antigen-specific immune response by the hydrophobicity of amphiphilic poly(γ-glutamic acid) nanoparticles.
Shima F; Akagi T; Uto T; Akashi M
Biomaterials; 2013 Dec; 34(37):9709-16. PubMed ID: 24016848
[TBL] [Abstract][Full Text] [Related]
37. APC targeted micelle for enhanced intradermal delivery of hepatitis B DNA vaccine.
Layek B; Lipp L; Singh J
J Control Release; 2015 Jun; 207():143-53. PubMed ID: 25886704
[TBL] [Abstract][Full Text] [Related]
38. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles.
Jesus S; Soares E; Costa J; Borchard G; Borges O
Int J Pharm; 2016 May; 504(1-2):59-69. PubMed ID: 26976502
[TBL] [Abstract][Full Text] [Related]
39. Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens.
Chuai X; Chen P; Chen H; Wang W; Deng Y; Ruan L; Li W; Tan W
J Viral Hepat; 2017 Apr; 24(4):337-345. PubMed ID: 27885748
[TBL] [Abstract][Full Text] [Related]
40. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars.
Tonnis WF; Amorij JP; Vreeman MA; Frijlink HW; Kersten GF; Hinrichs WL
Eur J Pharm Sci; 2014 May; 55():36-45. PubMed ID: 24468629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
